The common denominator is BTA. Incapable of/deliberately not attracting interest in relenza, or LANI.
Peter Cook is too worried real companies with real management will notice BTA and dislodge him like the parasite he is, just as he's settling in to quietly suck BTA dry.
The Lotus Eaters need to go.
BTA should be evolving into a manufacturer of products based on our intellectual property. That way we would still have income after the patents expire. Management are using BTA like a mine, dig it up and flog it off, move on. No intention of giving the shareholders a dividend, no idea how to build, just losses, failed expansion into America, failed litigation, when it's gone, move on.
We should negotiate LANI manufacture licence for Australia and NZ with our partner. Build a factory. Then develop HRV antiviral alone and sell a cure to the common cold to the world.
BTA Price at posting:
$1.38 Sentiment: Hold Disclosure: Held
